Related publication:
Related readings: China mulls tailored insurance

Insurance for Chinese drug companies regarding adverse drug reactions has been postponed for nearly six months, according to China Business News.

"Insurance companies need to conduct many more assessments for such a commercial insurance product. They will consider not only the social benefits but also the economic benefits," said Du Wenmin, deputy director of the Center for Adverse Drug Reactions Monitoring of Shanghai.

...

The full text is available in the  June Issue of China Insurance.